Arkansas Attorney General Leslie Rutledge on Thursday declared Arkansas has reached a multistate agreement in theory with the pharmaceutical distributor Reckitt Benckiser group (Reckitt). The agreement settles any allegations that the company improperly marketed or promoted the drug Suboxone, resulting in improper expenditures of state cash.
“Arkansans have suffered enough at the hands of opioid distributors like Reckitt,” aforementioned professional General Rutledge. “This corporation has double-dipped the health care system by deceivingly advertising to physicians that Suboxone is safe, and later received health care reimbursements for the falsely-marketed drug.”
This England-based company had, until December 23, 2014, a subsidiary named Reckitt Benckiser pharmaceuticals, Inc. (RPI). RPI distributed, marketed and sold Suboxone within the USA. The drug contains a mix of buprenorphine (an opioid) and antagonist (an opioid antagonist) and was approved to suppress opioid withdrawal symptoms as a district of a whole treatment plan to embody substance and psychosocial support. However, when used alone, this drug has resulted in opioid addiction.
Reckitt pays a whole of $700 million bucks in resolution of various civil fraud allegations impacting health care and completely different government health care programs, of that over $400 million will get within the health care program. The total health care settlement for Arkansas is $462,948.97.
Along with that, Reckitt will enter into a separate non-prosecution agreement with the U.S. Attorney’s geographic point for the Western District of Virginia and additionally the U.S. Department of Justice’s shopper Protection Branch.